Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk.
about
Hepatitis B virus and hepatitis C virus infection in healthcare workersGenotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern AfricaSufficient blood, safe blood: can we have both?Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt--that is the question.Fragment merger: an online tool to merge overlapping long sequence fragments.Molecular characterization of hepatitis B virus in liver disease patients and asymptomatic carriers of the virus in SudanHepatitis B virus DNA viral load determination in hepatitis B surface antigen-negative Swiss blood donors.Molecular virology in transfusion medicine laboratory.Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infectionA mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections.Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections.Hepatitis B virus subgenotype A1 predominates in liver disease patients from Kerala, IndiaFactors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus.Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review.Role of molecular diagnostics in the management of viral hepatitis B.Transfusion transmitted infections in thalassaemics: need for reappraisal of blood screening strategy in India.Comparison of Procleix Ultrio Elite and Procleix Ultrio NAT Assays for Screening of Transfusion Transmitted Infections among Blood Donors in India.Two cases of transfusion-transmitted hepatitis B virus (HBV) infection in a low-endemic country before implementation of HBV nucleic acid testing.Screening and diagnosis of HBV in low-income and middle-income countries.Hepatitis B virus sequencing and liver fibrosis evaluation in HIV/HBV co-infected Nigerians.Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China.Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc TestingHead-to-head comparison between two screening systems for HBsAG, anti-HBc, anti-HCV and HIV combination immunoassays in an international, multicentre evaluation study.Inclusion of human immunodeficiency virus Type 2 (HIV-2) in a multiplex transcription-mediated amplification assay does not affect detection of HIV-1 and hepatitis B and C virus genotypes: a multicenter performance evaluation study.Comparison between screening and confirmatory serological assays in blood donors in a region of South Italy.A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening.Comparative analysis of triplex nucleic acid test assays in United States blood donors.Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay.Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?Apheresis in developing countries around the World.Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.A simple and rapid capillary chemiluminescence immunoassay for quantitatively detecting human serum HBsAg.Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives
P2860
Q26765801-F06A34C6-3D88-4FDF-BABE-ECDE14091811Q28484102-35B6D6D4-93F5-43A4-A817-DE965CCAD301Q34206713-2D5645B0-EA8B-42F4-AEF4-2FE8A8AEA154Q34437586-67316FF9-594C-4943-B65B-2F0C0AB66F1BQ34617779-4FDA566C-7A6C-4CF3-A030-AF65FE72740CQ34832871-760A41AE-A13A-4150-BAB1-58A6302D8655Q35164580-B5CBE99B-B967-43EB-9A21-E2EB5C6326CFQ36766449-23053C67-6BE3-4A40-AD15-F22A8B0D7F60Q36766479-01919C83-FC77-423C-9926-20A841B296A3Q37305718-0E4F8AEF-3A93-47EE-B457-45E9436B4AD6Q37333836-0B6130E4-FE12-4C5F-B526-11D205BC3200Q37439918-5715BE62-8930-4968-994D-F87F07409DE4Q37618604-DB39EAEC-9A3A-4264-820E-2EB30F3F995DQ38038274-17EC255C-C8E2-41CE-BF9A-5D581F42DB66Q38088408-A874C23F-A262-46AA-B124-6999F65192FDQ38194183-227A7F82-643E-4DD6-AF30-CD1E5AB8A99FQ38283607-08124904-57FC-40BC-9F62-A2562AD8E971Q38403039-EAA8E2EF-5507-4E1D-A16B-3D74E6732845Q38953790-92A6FBE7-2E8C-47AF-AF84-C6FB0F19CC3EQ40258634-799FACA9-7277-445B-9110-B4F0A4746A3FQ40613598-659C2883-EA39-4D92-B789-056CAA7ED671Q41111337-9D73CCD9-71D2-44CB-BB7B-6FE3AFC13B3DQ41300211-53C7678C-B007-4C76-AF6A-4012121FC51CQ41647666-CBB35A23-107F-4CD7-A0A1-5CED789C4480Q42240158-EEC90A77-A863-42CE-9CBD-CA67B279A326Q42257442-22A43AE3-61E7-4C16-B938-8EF386DB8A30Q42990781-CC081791-D553-4341-B2EE-CFD32C4676DAQ44164538-DFC543AE-2123-436E-A3DB-9923B8DE7D25Q45351561-26033BBC-0A9D-4899-A131-9570146DC513Q46114694-E2849637-A88E-4FE4-82E9-8E3BCC3F974FQ48097119-4454D151-5213-488E-9D52-92974EA0271BQ50895974-AF23A12B-44D4-47E0-AEB6-66CDF5270E26Q58999805-DFFC1B6B-480B-45F6-B35A-424335EA2FA2
P2860
Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Hepatitis B virus transmission ...... d observed window period risk.
@en
Hepatitis B virus transmission ...... d observed window period risk.
@nl
type
label
Hepatitis B virus transmission ...... d observed window period risk.
@en
Hepatitis B virus transmission ...... d observed window period risk.
@nl
prefLabel
Hepatitis B virus transmission ...... d observed window period risk.
@en
Hepatitis B virus transmission ...... d observed window period risk.
@nl
P2093
P2860
P1433
P1476
Hepatitis B virus transmission ...... nd observed window period risk
@en
P2093
Caroline Dickens
Charl Coleman
Evangelia Walker
Mark Keyter
Nico Lelie
Ravi Reddy
Robert Crookes
P2860
P304
P356
10.1111/J.1537-2995.2011.03355.X
P577
2011-10-07T00:00:00Z